World Health Organization Issues Alert Over Critical Lack of Obesity Injections

Less than 10% of individuals that would benefit from obesity jabs such as Wegovy have access to them, states the global health agency as it issues its initial recommendations on the drugs.

Given more than one billion people worldwide now obese, it is urging increased and just availability to these injectable treatments.

According to projections, more than two billion could be obese by 2030 if no action is taken.

"Our new guidelines acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and distribution challenges are significant barriers to broad access to the jabs that can assist patients in reducing significant weight, explains the organization.

Skinny Jab Supply Crisis

Despite the present best projected scenario, the manufacturing of such drugs would only suffice for about 100 million people – less than 10% of the global need, per the health organization.

The advice encourages countries and companies to expand availability, by measures like licensing agreements.

The intellectual property rights on a key compound – the primary ingredient of a leading brand – is due to expire in a number of nations in 2026.

The Way Weight-Loss Jabs Function

These medications mimick a biological compound to delay gastric emptying, reduce hunger and enhance the sense of being full so people eat less.

Individuals usually see weight reduction after several weeks of starting on the once-weekly jabs.

Research points to people may put most of the weight back on within a year of stopping the medication, when their normal hunger return.

Being carrying excess weight increases your risk for experiencing medical conditions, such as type 2 diabetes, heart disease, stroke, and specific cancers.

Excess weight concerns people in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.